Microbial Contract Biomanufacturing Market, 2020-2030

BARRINGTON, Ill. - Dec. 23, 2020 - PRLog -- Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various aspects of their respective microbial biologic development programs.

Key Market Insights

Over 115 CMOs claim to offer manufacturing services for microbial biologics

The microbial contract biomanufacturing market is highly fragmented, featuring a mix of small, mid-sized, large and very large players. It is worth mentioning that more than 50% of CMOs mentioned in the report, have the necessary capabilities to manufacture biologics across all scales of operation (preclinical, clinical and commercial).

Presently, more than 70% of service providers use bacterial expression systems

Recently, a number of microbial biologics manufacturers are shifting to yeast-based production systems. It is also worth highlighting that close to 30% of CMOs, identified in this research, claim to have the required capabilities to manufacture biologics using both bacterial and yeast-based systems.

Europe is currently regarded as a key manufacturing hub for microbial biologics

There are more than 150 manufacturing facilities, with microbial fermentation capabilities, worldwide; of these, 43% are in Europe, followed by North America (31%). On the other hand, prominent regions in the Asia Pacific and Middle East, where microbial biologics are manufactured, include (in decreasing order of number of resident manufacturing facilities) China, India, Japan, Australia and Israel.

Several partnerships were established in this domain, during the period 2016-2020

Majority of the deals recorded in the report, were established in 2019. Further, a large number (~25%) of the partnerships were observed to be focused on the production of microbial biologics; this is followed by process development and manufacturing agreements (20%).

Further, multiple expansion initiatives were undertaken by CMOs, since 2016

For additional details, please visit

https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

1.      Drug Repurposing Service Providers Market, 2020 – 2030 (https://www.rootsanalysis.com/reports/drug-repurposing-service-provides.html)

2.      Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030

Contact:

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

Gaurav.Chaudhary@rootsanalysis.com